GlassScriptPhysician profile
Monika Benner
NPI 1871081711
$14,174.83
in general payments reported to CMS, 2019-2025
65 companies · $3,347 in 2025
The $3,347 reported for 2025 was more than what 97% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,893 · 2022: $2,302 · 2023: $2,703 · 2024: $2,930 · 2025: $3,347.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,226 · Long Term Medical Supply Or Device Loan: $1,180 · Education: $573.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,226.39 |
| Long Term Medical Supply Or Device Loan | $1,180.03 |
| Education | $573.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,545.16 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,886.37 | 2021-2025 | Calquence, Lynparza, Enhertu |
| Lilly USA, LLC | $684.46 | 2021-2025 | Verzenio, Jaypirca, Retevmo |
| Merck Sharp & Dohme LLC | $574.88 | 2021-2025 | Keytruda, Lynparza |
| Pfizer INC. | $529.34 | 2022-2025 | |
| Janssen Biotech, INC. | $487.58 | 2021-2025 | Rybrevant, Tecvayli, Darzalex |
| Abbvie INC. | $482.69 | 2021-2025 | |
| Astellas Pharma US INC | $460.09 | 2021-2025 | Padcev, Xtandi, Vyloy |
| Incyte Corporation | $445.10 | 2021-2024 | Jakafi |
| Daiichi Sankyo INC. | $439.14 | 2022-2025 | Enhertu, Injectafer, Datroway |
| Amgen INC. | $420.56 | 2021-2024 | Lumakras, Blincyto, Kyprolis |
| Regeneron Healthcare Solutions, INC. | $409.62 | 2021-2025 | Libtayo |
| Takeda Pharmaceuticals U.S.A., INC. | $392.00 | 2021-2025 | Ninlaro, Alunbrig |
| E.R. Squibb & Sons, L.L.C. | $304.34 | 2021-2025 | Opdivo, Eliquis |
| Pharmacyclics LLC, An Abbvie Company | $295.34 | 2021-2023 | Imbruvica |
Show all 65 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $243.42 | 2022-2025 | Jemperli, Zejula, Ojjaara |
| Rigel Pharmaceuticals, INC. | $213.27 | 2021-2023 | Rezlidhia, Tavalisse |
| Array Biopharma INC | $208.44 | 2021-2025 | Braftovi, Mektovi, Lorbrena |
| Sanofi-Aventis U.S. LLC | $199.75 | 2021-2022 | |
| Seagen INC. | $197.39 | 2021-2023 | Padcev, Tukysa |
| Adc Therapeutics America, INC. | $179.21 | 2022-2025 | |
| Genzyme Corporation | $160.03 | 2021-2025 | |
| Celgene Corporation | $155.02 | 2021-2025 | Reblozyl, Pomalyst |
| Genentech USA, INC. | $147.13 | 2021-2025 | Venclexta, Polivy, Tecentriq |
| Emd Serono, INC. | $132.15 | 2022-2025 | Bavencio |
| Alexion Pharmaceuticals, INC. | $124.00 | 2021-2025 | Ultomiris |
| Eisai INC. | $123.07 | 2021-2023 | |
| Gilead Sciences, INC. | $104.48 | 2021-2025 | Trodelvy |
| Bayer Healthcare Pharmaceuticals INC. | $102.06 | 2021-2025 | |
| G1 Therapeutics, INC. | $98.56 | 2022-2023 | Cosela |
| Beigene USA, INC. | $90.80 | 2022-2025 | Brukinsa, Tevimbra |
| Agios Pharmaceuticals, INC. | $86.17 | 2023-2025 | Pyrukynd |
| Jazz Pharmaceuticals INC. | $77.41 | 2021-2025 | |
| Tersera Therapeutics LLC | $68.55 | 2025 | Xermelo, Zoladex |
| Springworks Therapeutics, INC. | $57.15 | 2025 | Ogsiveo |
| Taiho Oncology, INC. | $57.01 | 2025 | |
| Beone Medicines USA, INC. | $55.93 | 2025 | Tevimbra, Brukinsa |
| Aveo Pharmaceuticals, INC. | $54.84 | 2022-2024 | |
| Ipsen Biopharmaceuticals, INC | $53.34 | 2022-2025 | Onivyde |
| Tempus Ai, INC | $53.04 | 2024 | |
| Kite Pharma, INC. | $47.15 | 2022-2023 | Yescarta |
| Sumitomo Pharma America, INC. | $45.80 | 2024-2025 | Orgovyx |
| Blueprint Medicines Corporation | $45.71 | 2023 | Ayvakit |
| Morphosys, US INC. | $44.10 | 2021-2023 | Monjuvi |
| Karyopharm Therapeutics INC. | $43.31 | 2021-2023 | Xpovio |
| Mirati Therapeutics, INC. | $41.73 | 2023-2024 | Krazati |
| Servier Pharmaceuticals LLC | $40.98 | 2022-2024 | |
| Puma Biotechnology, INC. | $40.84 | 2021-2024 | |
| Exelixis INC. | $39.51 | 2021-2023 | Cabometyx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.80 | 2025 | |
| Sobi, INC | $36.87 | 2024-2025 | |
| Myovant Sciences INC. | $36.46 | 2021 | |
| Geron Corporation | $34.12 | 2025 | Rytelo |
| Amneal Pharmaceuticals LLC | $27.00 | 2025 | Alymsys |
| Syndax Pharmaceuticals, INC. | $25.90 | 2025 | |
| Janssen Pharmaceuticals, INC | $25.86 | 2023-2024 | Xarelto |
| Blue Earth Diagnostics | $22.93 | 2024 | |
| Recordati_rare_diseases_inc. | $20.70 | 2024 | Sylvant |
| Azurity Pharmaceuticals, INC. | $19.92 | 2025 | Danziten |
| Deciphera Pharmaceuticals INC. | $19.02 | 2024 | Qinlock |
| Ge Healthcare | $18.07 | 2022 | |
| Tolmar Pharmaceuticals, INC. | $18.05 | 2022 | |
| Progenics Pharmaceuticals, INC. | $16.83 | 2023 | Pylarify |
| Fennec Pharmaceuticals, INC. | $14.66 | 2024 | Pedmark |
| Dova Pharmaceuticals | $12.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monika Benner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.